Market Currents
Acadia (ACAD) shares more than triple in value after being freed from a trading halt following...
-
Tuesday, November 27, 2012, 8:38 AM ETAcadia (ACAD) shares more than triple in value after being freed from a trading halt following news that its pimavanserin drug reduced psychotic episodes in patients with Parkinson's disease compared with a placebo in a Phase III trial. Acadia now needs to conduct another late-stage study to confirm the results - two similar trials failed to show a substantial fall in psychotic episodes.
Other date
Latest Articles
